Unknown

Dataset Information

0

ESMO20 YO for YO: highlights on metastatic renal cell carcinoma-the CheckMate-9ER trial.

ABSTRACT:

SUBMITTER: Kfoury M 

PROVIDER: S-EPMC7807955 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

ESMO20 YO for YO: highlights on metastatic renal cell carcinoma-the CheckMate-9ER trial.

Kfoury M M   Oing C C  

ESMO open 20210104 1

Similar Datasets

Unknown ESMO20 YO for YO: highlights on upper GI tumours.
| S-EPMC7807969 | biostudies-literature
Unknown ESMO20 YO for YO: highlights on oncogene-addicted NSCLC.
| S-EPMC7807911 | biostudies-literature
Unknown ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer.
| S-EPMC7910743 | biostudies-literature
Unknown ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib.
| S-EPMC7910735 | biostudies-literature
Unknown ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer.
| S-EPMC7910736 | biostudies-literature
Unknown Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma.
| S-EPMC9905187 | biostudies-literature
Unknown Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
| S-EPMC11046044 | biostudies-literature
Unknown Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.
| S-EPMC9750497 | biostudies-literature
Unknown Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
| S-EPMC9479564 | biostudies-literature
Unknown Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
| S-EPMC10305087 | biostudies-literature